Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by a preferential involvement of both upper and lower motor neurons. Evidence from neuroimaging and post-mortem studies confirms additional involvement of brain regions extending beyond the motor cortex. The aim of this study was to assess the extent of cerebral disease in ALS crosssectionally and longitudinally, and to compare the findings with a recently proposed diseasestaging model of ALS pathology. Deformation-based morphometry (DBM) was used to identify the patterns of brain atrophy associated with ALS and to assess their relationship with clinical symptoms. Longitudinal T1-weighted MRI data and clinical measures were acquired at baseline, 4 months, and 8 months, from 66 ALS patients and 43 age-matched controls who participated in the Canadian ALS Neuroimaging Consortium (CALSNIC) study. Whole brain voxel-wise mixed-effects modelling analysis showed extensive atrophy patterns differentiating ALS patients from the normal controls. Cerebral atrophy was present in the motor cortex and corticospinal tract, involving both GM and WM, and to a lesser extent in non-motor regions. More specifically, the results showed significant bilateral atrophy in the motor cortex, the corticospinal tract including the internal capsule and brainstem, with an overall pattern of ventricular enlargement; along with significant progressive longitudinal atrophy in the precentral gyrus, frontal and parietal white matter, accompanied by ventricular and sulcal enlargement. Atrophy in the precentral gyrus was significantly associated with greater disability as quantified with the ALS Functional Rating Scale-Revised (ALSFRS-R) (p<0.0001). The pattern of atrophy observed using DBM was consistent with the Brettschneider's four stage pathological model of the disease. Deformation based morphometry provides a sensitive indicator of atrophy in ALS, and has potential as a biomarker of disease burden, in both gray and white matter.
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder, with a highly selective involvement of the upper motor neurons (UMN) in the cortex and lower motor neurons (LMN) in the brainstem and spinal cord (Brownell et al., 1970; Martin and Swash, 1995) . This characteristic neuronal atrophy in the motor cortex is also accompanied by degeneration in the white matter tracts, most severely in the precentral areas and to a lesser extent elsewhere (Kushner et al., 1991) . Beyond the motor pathways, degeneration in the frontal and temporal lobes is the substrate for the cognitive deficits present in ALS (Strong, 2001) .
Onset of ALS symptoms is variable, and can include involvement of limb, bulbar or respiratory muscles or cognitive impairment. Spasticity, hyperflexia, and weakness result from UMN degeneration (Gordon, 2013) , whereas fasciculations, cramps and muscle wasting result from LMN degeneration (Hardiman et al., 2017) . Cognitive dysfunction also affects more than half of the patients, with evident frontotemporal dementia (FTD) in 15% (Wilson et al., 2001; Ringholz et al., 2005; Landau et al., 2012) . Approximately 30% of all patients have evidence of executive dysfunction at onset, and FTD is one of the presenting features in 13% of incident cases (Hardiman et al., 2017) .
Previous structural MR imaging studies have demonstrated brain changes arising from ALS, although with relatively poor sensitivity and specificity (Kato et al., 1993; Oba et al., 1993; Waragai, 1997; Andreadou et al., 1998; Hecht et al., 2001; Charil et al., 2009) . Voxel Based Morphometry (VBM) studies report a trend of grey matter loss in the motor cortex, and in frontotemporal regions especially for patients with cognitive deficits (Chang et al., 2005; Agosta et al., 2007 Agosta et al., , 2009 ). These regional studies have generally been performed in relatively small samples and have not yet produced conclusive evidence of motor cortex or corticospinal tract atrophy. To date, no MRI study has been able to provide a comprehensive picture of the brain regions that are involved in ALS, and conventional MRI still remains a tool to rule out disorders that mimic ALS rather than to confirm diagnosis or quantify disease burden.
In this study, we have used deformation-based morphometry (DBM) to quantify the patterns of disease-related brain changes in ALS. Unlike voxel-based morphometry (VBM), DBM does not rely on a prior tissue classification step, which might introduce errors into the measurements, particularly when the population under study presents with white matter hyperintensities on T2weighted images. This a relevant concern in ALS studies, where there is evidence of white matter tract alterations appearing as T2-weighted hyperintensities in a proportion of patients (Hecht et al., 2001) . Such errors might create systematic biases in VBM measurements. In addition, the image processing tools used in this study have been designed for use in multi-center datasets across different MRI systems, and are able to accommodate between-site variabilities.
Taking advantage of these superior methodological tools, the primary goal was to quantify accurately the patterns of disease-related brain changes in ALS and investigate the associations between such changes and clinical symptoms.
In addition, these in vivo changes were investigated in relation to the pathological staging system of Brettschneider et al. (Brettschneider et al., 2013) , that characterizes ALS in four stages based on the regional accumulation of transactive response DNA-binding protein 43kDa (TDP-43).
Stage one is characterized by involvement of the primary motor cortex, alpha motor neurons in the ventral horn of the spinal cord, and brainstem motor nuclei of cranial nerves V, VII, and X-XII. Stage two adds involvement of the prefrontal neocortex, reticular formation and the inferior olivary complex. In stage three, TDP-43 deposition is now present more extensively in the prefrontal and postcentral neocortex and striatum. Stage four additionally involves the anteromedial portions of the temporal lobe, including the hippocampal formation. It was investigated whether brain atrophy, estimated by DBM analysis, followed the Brettschneider stages of ALS pathology. Each participating centre in CALSNIC followed identical standard operating procedures for clinical evaluations and harmonized acquisition protocols for brain imaging. Data from four sites were included: University of Alberta, University of Calgary, University of Toronto, and McGill University. All participants gave written informed consent and the study was approved by the health research ethics boards at each of the participating sites. Participants were included if they had sporadic or familial ALS, and met El Escorial criteria for possible, probable, probable laboratory supported, or definite ALS (Brooks et al., 2000) . Participants were excluded if they had a history of other neurological or psychiatric disorders, prior brain injury, or respiratory impairment resulting in an inability to tolerate the MRI protocol. 
Materials and Methods

Participants
MRI Processing
All T1-weighted MRI data were pre-processed using the Medical Imaging Network Common dataform (MINC) toolkit of the Montreal Neurological Institute (MNI), publicly available at https://github.com/BIC-MNI/minc-tools, using the following steps: 1) denoising (Coupe et al., 2008) ; 2) intensity inhomogeneity correction (Sled et al., 1998) ; and 3) image intensity normalization into intensity range [0-100] according to a linear histogram matching algorithm.
All images were first linearly (Dadar et al., 2018a) and then nonlinearly (Avants et al., 2008) registered to an average template recognized by the International Consortium for Brain Mapping (ICBM), MNI-ICBM152 (Fonov et al., 2009 ). The quality of the registrations was visually assessed, confirming that all imaging data were accurately registered to the template.
Using MINC tools, DBM maps were obtained by computing the Jacobian of the estimated nonlinear deformation field. DBM maps reflect the local differences between the average MNI-ICBM152 template (Fonov et al., 2009 ) and images of a given participant, with values larger than one indicating expansion (e.g. larger sulci or ventricles) and values smaller than one indicating shrinkage (e.g. atrophy). Voxel-wise DBM maps were used to assess the global brain differences between controls and ALS patients. Mean DBM values across regions of interest were used to assess the relationship between regional atrophy and clinical measurements.
Statistical Analyses
To investigate brain changes related to ALS in relation to the confounds of normative aging as well as sex differences, a regression procedure was developed involving the images from the age-matched controls, as similarly performed in previous studies (La Joie et al., 2012; Moradi et al., 2015; Zeighami et al., 2017; Brown et al., 2019) ). The following voxel-wise mixed effects models were estimated based on the controls:
where DBM indicates the DBM value at a certain voxel in the brain; Age indicates the participant's age at the time of imaging; Sex (Male/Female) is a categorical variable; and ID and
Center are categorical random variables, indicating the control participant's ID and the data acquisition center. Based on the model estimates, normative aging and sex effects were then regressed out from the patients. The following mixed effects models were used to estimate the ALS-specific brain changes in the patients, accounting for confounds:
Here, DBMr are the residualized DBM values (after regressing out age and sex based on controls, i.e. eq. 1), also referred to in the literature as a W-score map (La Joie et al., 2012; Brown et al., 2019) . The resulting maps were corrected for multiple comparisons using False Discovery Rate (FDR) with a significance threshold of 0.05.
In addition, mean DBM values were calculated for the corticospinal tract mask obtained from Yeh et al. (Yeh et al., 2018) , as well as the frontal lobe, frontotemporal lobe, precentral gyrus, and dorsolateral prefrontal cortex masks obtained from a grey matter atlas for the MNI-ICBM152 template (Manera et al., 2019) . The average values were used in the following regionof-interest (ROI) analyses: 
Results
Table 2 summarizes the demographic information as well as the clinical scores for the participants used in this study. Dichotomization details: ECAS: Total score, using 2 SD based on controls as cut-off. ALSexi: Total score, using 2 SD based on controls as cut-off. UMN Burden: above/below ("High/Low") median value. Progression Rate: above/below ("High/Low") median value. Similarly, Figure 2 shows the t-statistics maps reflecting the significant brain changes with age (after FDR correction) only in the ALS cohort. As normative aging has already been regressed out from the model, these remaining changes are the ongoing additional changes specific to the disease occurring during imaging conducted longitudinally over time. The results show additional atrophy in the precentral gyrus that is more pronounced on the right, as well as diffuse atrophy in frontal and parietal white matter and ventricular and sulcal enlargement. Table 3 shows the associations between clinical measures and regional atrophy. Mean DBM values in the precentral gyrus were significantly and positively associated with ALSFRS-R,
indicating that a lower DBM value (i.e. greater atrophy) related to a lower score in ALSFRS-R (i.e. greater disability). Similarly, mean DBM value in the corticospinal tract was positively associated with ALSFRS-R, but this relationship did not survive multiple comparison correction (uncorrected p-value = 0.03). There was also a trend towards an association between lower mean DBM value in the dorsolateral prefrontal cortex and greater executive impairment (uncorrected p-value = 0.08). 
Disease Staging and Projection of Progression in Atrophy
It is not unreasonable to assume that, in ALS, the greatest brain atrophy is found in areas that have been affected the longest by the disease. Using different threshold values on the t-statistics map shown in Figure 1 , four stages of the disease were identified based on the brain regions involved and the magnitude of tissue shrinkage (Figure 3) . These stages were consistent with the ALS stages defined based on previous pathologic staging studies (Brettschneider et al., 2013) . Figure 3 shows the spread of brain atrophy and its correspondence with pathologic stages as defined by Brettschneider et al. (Brettschneider et al. 2013 ). Fig. 3 . Comparison of disease stages based on magnitude of atrophy and histological stages. The first row indicates the four pathological stages based on Brettschneider et al. (2013) as well as a corresponding sagittal slice from the tstatistics map (Figure 2 ). The second row shows three sagittal, coronal, and axial slices overlayed with the tstatistics map values thresholded at t-values= -5, -4, -3, and -1.5, to correspond with stages 1-4, respectively.
Discussion
In this study, using DBM and taking advantage of the large multi-center cohort of ALS patients available from CALSNIC, it was possible to reveal the extensive atrophy pattern characteristic of ALS: bilateral atrophy in the motor cortex and the corticospinal tract including the internal capsule and brainstem, and an overall pattern of ventricular enlargement, along with additional longitudinal atrophy in the bilateral precentral gyri, diffuse white matter, as well as ventricular and cortical sulcus enlargement. The pattern of atrophy described in this paper (Figure 3) is consistent with pathologically defined stages in ALS (Brettschneider et al. 2013 ). Furthermore, atrophy in the precentral gyrus significantly correlated with disability as assessed with the ALSFRS-R (p<0.0001), similar to a previous study (Sheng et al., 2015) .
Previous imaging studies have reported similar patterns of atrophy, although not as comprehensively in general. For example, VBM studies have reported GM reduction in motor, premotor, basal ganglia and frontotemporal regions (Chang et al., 2005; Agosta et al., 2007; Thivard et al., 2007; Agosta et al., 2009; Senda et al., 2011; Sheng et al., 2015; Shen et al., 2016; Buhour et al., 2017; Kim et al., 2017 , Chen et al., 2018b Menke et al., 2018) . Cortical thickness studies have reported cortical thinning in the motor cortex as well as frontal and temporal areas (Roccatagliata et al., 2009; Verstraete et al., 2012 , Chen et al., 2018c . A recent meta-analysis reported significant WM reduction in the bilateral supplementary motor areas, precentral gyri, left middle cerebral peduncle, and right cerebellum, involving the corticospinal tract, interhemispheric fibres, subcortical arcuate fibres, and the projection fibres to the striatum and cortico-ponto-cerebral tract (Chen et al., 2018a) .
The atrophy map obtained in this study provides an in-vivo confirmation for the sequentially increasing pathology in alignment with Brettschneider model (Brettschneider et al. 2013 ). This sequential pattern of disease progression has also been reported in diffusion tensor imaging studies (Kassubek et al., 2014; Müller et al., 2016; Schmidt et al., 2016) . Further studies are necessary to determine the nature of the underlying biological changes (microstructural damage, macrostructural atrophy, or a combination) that are observed in T1w and DTI data. To our knowledge, no previous morphometric study of ALS has succeeded to show the correspondence between the pattern of gray and white matter atrophy and disease stages defined by TDP-43 spreading (Brettschneider et al. 2013) . Using different threshold values on the t-statistics map (reflecting the severity of atrophy specific to ALS), the four stages described by Brettschneider et al. were identified (Figure 3) . The possibility to determine disease stage, and pathological propagation, using structural MRI could have potential implications in the clinical setting.
Indeed, using already available and routinely used MRI, non motor progression of symptoms (i.e. cognitive impairment) could be anticipated. Further studies are necessary to investigate the sensitivity of using structural MRI at the level of an individual participant.
The present study has several advantages compared with the previous reports. The multi-center CALSNIC cohort included 66 ALS patients, a larger sample size compared with previous studies (Sheng et al., 2015) . The MRI scans were also acquired with higher magnetic field strength (i.e.
3T rather than 1.5T), yielding images with better contrast. All the image processing tools used in this study have been developed and extensively validated for use in multi-center studies involving different MRI systems, and have been used in numerous such studies (Zeighami et al., 2015 , Dadar et al., 2018b Misquitta et al., 2018; Dadar et al., 2019; Manera et al., 2019; Sanford et al., 2019) . In addition, all analyses included center as a categorical random effect to ensure that any residual variability across centers would not bias the results.
We acknowledge that there were limitations to the present study. Not all participants completed all three visits, although the proportion of the number of follow-up visits to baseline were similar across patient and control groups. In addition, the follow-up period (8 months) is relatively short.
Future studies investigating DBM changes in ALS with longer follow-ups are warranted, though there are inherent constraints in recruiting such a cohort.
In conclusion, DBM reveals the atrophy pattern characteristic of ALS consistent with previous pathological findings, both in gray and white matter areas and can be used to obtain a quantitative measure of disease burden. DBM measurements might therefore have the potential to be a biomarker in ALS.
